loading page

SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate
  • Manuel Becerra-Flores,
  • Timothy Cardozo
Manuel Becerra-Flores
NYU Langone Health

Corresponding Author:[email protected]

Author Profile
Timothy Cardozo
Author Profile

Abstract

Aim: The COVID pandemic is caused by infection with the SARS-CoV-2 virus. The major mutation detected to date in the SARS-CoV-2 viral envelope spike protein, which is responsible for virus attachment to the host and is also the main target for host antibodies, is a mutation of an aspartate (D) at position 614 found frequently in Chinese strains to a glycine (G). We sought to infer health impact of this mutation. Result: Increased case fatality rate correlated strongly with the proportion of viruses bearing G614 on a country by country basis. The amino acid at position 614 occurs at an internal protein interface of the viral spike, and the presence of G at this position was calculated to destabilize a specific conformation of the viral spike, within which the key host receptor binding site is more accessible. Conclusion: These results imply that G614 is a more pathogenic strain of SARS-CoV-2, which may influence vaccine design. The prevalence of this form of the virus should also be included in epidemiologic models predicting the COVID-19 health burden and fatality over time in specific regions. Physicians should be aware of this characteristic of the virus to anticipate the clinical course of infection. What is known about this topic? Nothing is known about the health significance of the D614G SARS-CoV-2 variant. What does this article add? A molecular clue to viral molecular pathogenesis of COVID-19 disease.
14 Apr 2020Submitted to International Journal of Clinical Practice
17 Apr 2020Submission Checks Completed
17 Apr 2020Assigned to Editor
19 Apr 2020Reviewer(s) Assigned
26 Apr 2020Review(s) Completed, Editorial Evaluation Pending
28 Apr 20201st Revision Received
29 Apr 2020Assigned to Editor
29 Apr 2020Submission Checks Completed
29 Apr 2020Reviewer(s) Assigned
29 Apr 2020Review(s) Completed, Editorial Evaluation Pending
30 Apr 20202nd Revision Received
01 May 2020Reviewer(s) Assigned
01 May 2020Submission Checks Completed
01 May 2020Assigned to Editor
01 May 2020Review(s) Completed, Editorial Evaluation Pending
02 May 2020Editorial Decision: Accept